

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

Our Company was originally incorporated as “POCT Services Private Limited” on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to “Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to “Q-Line Biotech Limited”, and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **“History and Corporate Structure”** beginning on page 154 of the Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com
CIN: U74120UP2010PLC042528
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF Q-LINE BIOTECH LIMITED (“OUR COMPANY” OR “QLBL” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹[●] LAKHS (“PUBLIC ISSUE”) OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Our Company has undertaken a Pre-IPD Placement by way of private placement of 8,00,000 Equity Shares for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.

**Subject to finalization of Basis of Allotment.*

PRICE BAND: ₹ 326 TO ₹ 343 PER EQUITY SHARE OF FACE VALUE ₹10/- EACH

THE FLOOR PRICE (₹326) IS 32.6 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE (₹343) IS 34.3 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.
THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE (₹326) IS 11.39 TIMES AND AT THE CAP PRICE (₹343) IS 11.98 TIMES.
BIDS CAN BE MADE FOR A MINIMUM OF 800 EQUITY SHARES AND IN MULTIPLES OF 400 EQUITY SHARES THEREAFTER

Weighted average return on net worth for the last three fiscal years should be read as 23.17%

The details of the Fresh Issue and the post-Issue market Capitalisation of the Company, each at the Floor Price (₹326) and the Cap Price (₹343), are given below:

Particular	At Floor price of ₹326 per equity share		At Cap price of ₹343 per equity share	
	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)
Fresh Issue	62,53,200	20,385.43	62,53,200	21,448.48
Offer for Sale	-	-	-	-
Total Issue Size	62,53,200	20,385.43	62,53,200	21,448.48
Post-Issue Market Capitalization of the Company	2,33,28,199	76,049.93	2,33,28,199	80,015.72

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026
BID/ ISSUE OPENS ON: THURSDAY, MAY 21, 2026
BID/ ISSUE CLOSES ON: MONDAY, MAY 25, 2026 ^

^UPI mandate end time shall be at 05:00 p.m. on the Bid/Issue closing date.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

THIS ISSUE IS BEING MADE THROUGH BOOK BUILDING PROCESS, IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE “SEBI (ICDR) REGULATIONS”), AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACT (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”). FOR THE PURPOSE OF THE ISSUE, THE DESIGNATED STOCK EXCHANGE WILL BE NATIONAL STOCK EXCHANGE OF INDIA LIMITED.

ALLOCATION OF THE ISSUE

- **QIB PORTION** : NOT MORE THAN 50.00% OF THE NET ISSUE
 - **INDIVIDUAL PORTION** : NOT LESS THAN 35.00% OF THE NET ISSUE
- **NON-INSTITUTIONAL PORTION** : NOT LESS THAN 15.00% OF THE NET ISSUE
 - **MARKET MAKER PORTION** : UPTO 3,13,200 EQUITY SHARES OR 5.01% OF THE ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER, potential investors should only refer to this pre-issue and price band advertisement for the issue and should not rely on any media articles/ reports in relation to the valuation of the company as these are not endorsed, published or confirmed either by the company or the Book Running Read Manager to the issue (“BRLM”).

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated May 16, 2026 the above provided price band is justified based on quantitative factors/ KPIs disclosed in the ‘Basis for Issue Price’ section beginning on page 95 of the Red Herring Prospectus (‘RHP’) vis-a-vis the weighted average cost of acquisition (“WACA”) of primary and secondary transaction(s), as applicable, disclosed in ‘**Basis for Issue Price**’ section beginning on page 95 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS

For details refer to section titled “Risk Factors” on page 20 of the Red Herring Prospectus.

1. Risk to investors summary description of key risk factors based on materiality

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
 - Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
 - Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
 - We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
 - We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
 - For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
 - Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Anita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
 - Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
 - Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
 - We are subject to risks arising from exchange rate fluctuations.
- Average cost of acquisition of Equity Shares held by the Individual Promoters are:

Sr. No.	Name of Promoter	No. of Shares held	Average Cost of Acquisition (in ₹)
1.	Saurabh Garg	1,01,91,000	0.04
2.	Amita Garg	39,37,480	0.00
3.	Ayush Garg	31,500	0.00
4.	Ajay Kumar Mahanty	7,50,000	18.34
5.	Abhay Agrawal	7,56,010	0.00

And the Issue Price at the upper end of the Price Band is Rs. 343 per Equity Share.

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.

2. Details of suitable ratios of the company and its peer group for the latest full financial year:

Name of Company	Current Market Price (₹)	Face Value	EPS	PE	RoNW (%)	Book Value (₹)	Total Income (₹ In lakhs)
			Basic/Diluted				
Q-line Biotech Limited	[●]*	10	28.63	[●]^	23.74%	120.60	31,378.04

**CMP of our Company is considered as Issue Price. ^to be included post finalization of the Issue Price.*

Notes:

- The P/E ratio has been computed by dividing Market Price with EPS.
- The EPS, NAV, RoNW and total Income of our Company are taken as per Consolidated Restated Financial Statement for the Year March 31, 2025.
- NAV per share is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2025.
- RoNW has been computed as net profit after tax divided by closing net worth.
- Net worth has been computed in the manner as specified in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.
- The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [●] times the face value of equity share.

3. Weighted average return on net worth for the last 3 FYs:

As per restated financial statements:

Sr. No.	Period	RONW (%)	Weights
1.	Period ending March 31, 2025	23.74	3
2.	Period ending March 31, 2024	21.29	2
3.	Period ending March 31, 2023	25.20	1
	Weighted Average	23.17	6
4.	For the period ended December 31, 2025	16.88	

Note:

- The figures disclosed above are based on the Restated Consolidated Financial Statements of the Company.
- The RoNW has been computed by dividing restated net profit after tax (excluding exceptional items) attributable to owners of parent company with restated Net worth as at the end of the year/period.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.

4. Weighted average cost of acquisition of all the shares transacted in the three years, 18 months and one year preceding the date of the Red Herring Prospectus-

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price(in Rs.)
Last one year, Last 18 months & Last 3 years	17.88	19.18	0-343

5. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI:

a) The price per share of our Company based on the primary/ new issue of shares (equity/ convertible securities)

There has been no issuance of Equity Shares other than Equity Shares issued pursuant to a private placement on May 13, 2026, bonus issue on August 28, 2025 and right issue on September 27, 2025 during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale/ acquisition of shares (equity shares)

There have been no secondary sale/ acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days

c) Price per share based on the last five Primary Issuances or Secondary Transactions

Since there are no such transactions to report to under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter/ Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of the Red Herring Prospectus irrespective of the size of transactions, is as below:

Primary Transaction:

Date of Allotment	No. of equity shares allotted	Issue price per equity share (₹)	Nature of Allotment	Nature of consideration	Total Consideration
August 28, 2025	1,41,75,000	Nil	Bonus Issue	-	Nil
September 27, 2025	5,24,999	10/-	Right Issue	Cash	52,49,990
May 13, 2026	8,00,000	343/-	Private Placement	Cash	27,44,00,000

Secondary Transaction:

Date	Name of Transferor	Name of Transferee	No. of Shares	Price per share	Adjusted Price per share	Nature of transaction	Total Consideration
September 25, 2025	Pushplata Garg	Saurabh Garg	54,000	Nil	-	Gift	Nil
		Abhay Agrawal	75,600	Nil	-	Gift	Nil
June 06, 2025	Amita Garg	Amit Agarwal	3,150	Nil	-	Gift	Nil
		Ayush Garg	3,149	Nil	-	Gift	Nil
	Saurabh Garg	Shubham Garg	3,150	Nil	-	Gift	Nil

Continued on next page

Continued from previous page

Weighted average cost of acquisition & Issue price

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs 10/-)	Floor price (i.e. ₹326)	Cap price (i.e. ₹343)
Weighted average cost of acquisition of primary / new issue	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale / acquisition.	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances/ secondary transactions	17.89	18.22	19.17

Note:
^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Red Herring Prospectus.
^^There were no secondary transactions in last 18 months from the date of the Red Herring Prospectus.
The Issue Price shall be determined by our Company in consultation with the BRLMs, on the basis of the demand from investor for the Equity Shares through Book Building Process.

ADDITIONAL INFORMATION FOR INVESTORS:			
1. Details of proposed /undertaken pre-issue placements from the DRHP filing date – Our Company has undertaken a Pre-IPO Placement by way of private placement of 8,00,000 Equity Shares (4.92% of Pre Issue Capital) for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.			
Date of Allotment	Number of Equity Shares Allotted @ 343/-	Total Consideration	Name of Allottees
13.05.2026	4,35,502	14,93,77,186	Vikas Vijaykumar Khemani
	2,33,300	8,00,21,900	Calliope Capital Advisors LLP
	29,155	1,00,00,165	Sahastraa Advisors Private Limited
	29,155	1,00,00,165	SB Opportunities Fund II
	29,155	1,00,00,165	Deepak Malik
	29,155	1,00,00,165	Nisha Jain and Priyanka Havelia
	7,289	25,00,127	Kunal Niranjana Shah
	7,289	25,00,127	Rajkumar Mangilal Borana

- 2 Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date:** Not Applicable
- 3. Pre Issue Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company:**

S. No.	Pre-issue shareholding as at the date of Advertisement ⁽ⁱ⁾			Post-Issue shareholding as at Allotment ⁽ⁱⁱ⁾			
	Shareholders	Number of Equity Shares (2)	Share holding (in%) (2)	At the lower end of the price band (₹326) Number of Equity Shares (2)	Share holding (in %) (2)	At the upper end of the price band (₹343) Number of Equity Shares (2)	Share holding (in %) (2)
PROMOTER							
1.	Saurabh Garg	1,01,91,000	59.68	1,01,91,000	43.69%	1,01,91,000	43.69%
	Amita Garg	39,37,480	23.06	39,37,480	16.88%	39,37,480	16.88%
	Abhay Agrawal	7,56,010	4.43	7,56,010	3.24%	7,56,010	3.24%
	Ajay Kumar Mahanty	7,50,000	4.39	7,50,000	3.21%	7,50,000	3.21%
	Ayush Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
PROMOTER GROUP⁽ⁱ⁾							
2.	Amit Agarwal	31,510	0.18	31,510	0.14%	31,510	0.14%
	Shubham Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
	Pushplata Garg	21,000	0.12	21,000	0.09%	21,000	0.09%
ADDITIONAL TOP 10 SHAREHOLDERS							
3.	Vikas Vijaykumar Khemani	4,35,502	2.55	4,35,502	1.87%	4,35,502	1.87%
4.	Calliope Capital Advisors LLP	2,33,300	1.37	2,33,300	1.00%	2,33,300	1.00%
5.	Alok Kumar Agarwal	2,09,400	1.23	2,09,400	0.90%	2,09,400	0.90%
6.	Bishal Kumar	50,000	0.29	50,000	0.21%	50,000	0.21%
7.	Rajesh Kumar Upadhyay	40,000	0.23	40,000	0.17%	40,000	0.17%
8.	Dinesh Kantilal Doshi	32,000	0.19	32,000	0.14%	32,000	0.14%
9.	Bhupendra Singh Chuphal	32,000	0.19	32,000	0.14%	32,000	0.14%
10.	Amit Saraswat	32,000	0.19	32,000	0.14%	32,000	0.14%
11.	Anita Singhal	30,000	0.18	30,000	0.13%	30,000	0.13%
12.	Monika Raj	30,000	0.18	30,000	0.13%	30,000	0.13%
Total		1,68,74,202	98.82	1,68,74,202	72.33	1,68,74,202	72.33

- Notes:**
- 1) The Promoter Group shareholder is Pushplata Garg, Amit Agarwal and Shubham Garg.
- 2) Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.
- 3) Based on the Issue price of ₹(●) and subject to finalization of the basis of allotment.



BASIS FOR ISSUE PRICE

The **"Basis of the Issue Price"** on page 95 of the Offer document has been updated with the above price band. Please refer to the website of the BRLMs i.e. www.hemsecurities.com and www.shareindia.com for the **"Basis of the Issue Price"** updated with the above price band.
(You may scan the QR code for accessing the website of Hem Securities Limited and Share India Capital Services Private Limited)

Sequence of Activities	Listing within T+3 days (T is Issue Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Upto 4 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc.) – Upto 4 pm on T Day. Electronic Applications (Syndicate Individual Bidders, Non-Institutional Applications) – Upto 3 pm on T Day.
	Physical Applications (Bank ASBA) – Upto 1 pm on T Day. Physical Applications (Syndicate Individual Bidders, Non-Institutional Applications of QIBs and NIIs) – Upto 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day.
Bid Modification	From Issue opening date up to 4 pm on T Day.
Validation of bid details with depositories	From Issue opening date up to 5 pm on T Day.
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges – Sponsor Banks – NPCI and NPCI – PSPs/TPAPs* – Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timelines.	On daily basis
UPI Mandate acceptance time	T Day– 5 pm
Issue Closure T day	T Day – 4 pm for Individual Investor, QIB, NII and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day
Third party check on Non-UPI applications	On daily basis and to be completed before 1 pm on T+1 day
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA UPI ASBA	Before 09:30 pm on T+1 day All SCSBs for Direct ASBA – Before 07:30 pm on T Day Syndicate ASBA – Before 07:30 pm on T Day
Finalization of rejections and completion of basis	Before 6 pm on T+1 day.
Approval of basis by Stock Exchange	Before 9 pm on T+1 day
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank Corporate action execution for credit of shares	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer; Completion before 4 pm on T+2 day for unlocking Initiation before 2 pm on T+2 day Completion before 6 pm on T+2 day
Filing of listing application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day. In newspapers - on T+3 day but not later than T+4 day
Trading starts T+3 day	T+3 day

BOOK RUNNING LEAD MANAGERS TO THE ISSUE		REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
			
HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91-22-4906 0000 Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Sourabh Garg SEBI Registration Number: INM000010981 CIN: U67120RJ1995PLC010390		PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22-2301-2517 / 8261 Fax No.: +91-022-23012517 Email: nevisseu@shareindia.com Website: www.purvashare.com Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112	Akhand Pratap Singh Q-LINE BIOTECH LIMITED Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012 Telephone: +91 522-2435570 Email: akhand.singh@qlinebiotech.com Website: www.qlinebiotech.com CIN: U74120UP2010PLC042528 Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non- receipt of funds by electronic mode, etc. For all Issue related queries and for redressal of complaints investors may also write to the BRLMs.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of SEBI at <https://www.sebi.gov.in/>, website of the Company at www.qlinebiotech.com, the website of the BRLM to the Issue at <https://www.hemsecurities.com/>, the website of NSE at www.nseindia.com respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, BRLMs and NSE at www.qlinebiotech.com, <https://www.hemsecurities.com>, www.shareindia.com and www.nseindia.com, respectively.

SYNDICATE MEMBER: Hem Finlease Private Limited

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Q-Line Biotech Limited, Telephone: +91 522-2435570; BRLM: Hem Securities Limited, Telephone: +91-22-4906 0000 and the Syndicate Members: Hem Finlease Private Limited, Telephone: +91-141-4051000 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: HDFC Bank Limited.

UPI: UPI Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

Place: Lucknow, Uttar Pradesh
Date: May 16, 2026.

On behalf of Board of Directors
Q-Line Biotech Limited
Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

Disclaimer: Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares the Red Herring Prospectus dated May 16, 2026 has been filed with the Registrar of Companies, Uttar Pradesh-I and thereafter with SEBI and the Stock Exchanges. The Red Herring Prospectus is available on the website of the SEBI at <https://www.sebi.gov.in/>, website of NSE at <https://www.nseindia.com/companies-listing/corporate-filings-offer-documents> and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled **"Risk Factors"** beginning on page 20 of the Red Herring Prospectus.


The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **"Securities Act"**) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public issuing in the United States.

Bid/Issue Period (except the Bid/ Issue Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time ("IST"))
Bid/ Issue Closing Date* (i.e. Monday, May 25, 2026)	
Submission of Electronic Applications (Online ASBA through 3-in-1 accounts) – For Individual Investors other than QIBs and Non-Institutional Investors	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA applications)	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Syndicate Non- Individual Applications)	Only between 10.00 a.m. and up to 3.00 p.m. IST
Submission of Physical Applications (Bank ASBA)	Only between 10.00 a.m. and up to 1.00 p.m. IST
Submission of Physical Applications (Applications of QIBs and Non-Institutional Investors)	Only between 10.00 a.m. and up to 12.00 p.m. IST
Modification/ Revision/cancellation of Bids	
Upward Revision of Bids by Individual Investors, QIBs and Non-Institutional Investors categories #	Only between 10.00 a.m. on the Bid/Issue Opening Date and up to 4.00 p.m. IST on Bid/Issue Closing Date

*UPI mandate end time and date shall be at 5:00 pm on the Bid/Issue Closing Date
#Individual Investors, QIBs and Non-Institutional Investors can neither revise their bids downwards nor cancel/ withdraw their Bids. On the Bid/Issue Closing Date, the Bids shall be uploaded until: 4.00 p.m. IST in case of Bids by Individual Investors, QIBs and Non-Institutional Investors.

Event	Indicative Dates
Bid/ Issue Opening Date	Thursday, May 21, 2026
Bid/ Issue Closing Date	Monday, May 25, 2026
Finalization of Basis of Allotment with the Designated Stock Exchange (T+1)	Tuesday, May 26, 2026
Initiation of Allotment/ Refunds/ Unblocking of Funds from ASBA Account or UPI Id Linked Bank Account (T+2)	Wednesday, May 27, 2026
Credit of Equity Shares to Demat Accounts of Allottees (T+2)	Wednesday, May 27, 2026
Commencement of Trading of The Equity Shares on the Stock Exchange (T+3)	Friday, May 29, 2026

ASBA*



Simple, Safe, Smart way of Application- Make use of it!!!

***Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.**

Mandatory in Public Issues from January 01, 2016. No cheque will be accepted

UPI – Now available in ASBA for Individual investors and Non-Institutional investor applying for amount up to ₹5,00,000/- applying through Registered Brokers, DP's & RTAs. UPI Bidder also have the option to submit the Application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the Bank Account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CDDT notification dated February 13, 2020, issued by the CDDT and the subsequent press release, including press release dated June 25, 2021 and September 17, 2021 and CDDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by (i) Individual Investors Portion. (ii) Non-Institutional Investors with an application size of up to ₹5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the link: www.sebi.gov.in. UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited has been appointed as Sponsor Banks for the Issue, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail id: ipo_upi@npci.org.in.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three (3) additional working days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten (10) working days. In cases of force majeure, banking strike or similar circumstances, our Company in consultation with the Book Running Lead Manager for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one (1) working day, subject to the Bid/Issue Period not exceeding ten (10) working days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the website of the Book Running Lead Manager and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), other Designated Intermediaries and the Sponsor Banks, as applicable.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253(1) and 253(2) of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). Pursuant to the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Third Amendment) Regulations, 2025, out of the Anchor Investor Portion, 40% shall be reserved, of which (i) 33.33% shall be available for allocation to domestic Mutual Funds and (ii) 6.67% shall be available for allocation to life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies, and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription under (ii) above, the allocation may be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the remaining QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, states that not less than 35% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investors shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) (Amendment) Regulations, 2025. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled **"Issue Procedure"** on page 343 of the Red Herring Prospectus.

Bidders/ Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAR and are in compliance with CDDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see **"History and Corporate Structure"** on page 154 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section **"Material Contracts and Documents for Inspection"** on page 383 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The liability of the member(s) is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on the date of Red Herring Prospectus, the Authorized share Capital of the Company is Rs. 25,00,00,000/- (Rupees Twenty-Five Crore only) divided into 2,50,00,000 (Two Crore Fifty Lakhs) Equity Shares of face value of Rs.10/- each. The issued, subscribed and paid-up share capital of the Company before the Issue Rs. 17,07,49,990/- (Rupees Seventeen Crore Seven Lakh Forty-Nine Thousand Nine Hundred and Ninety Only) divided into 1,70,74,999 (One Crore Seventy Lakhs Seventy-Four Thousand Nine Hundred Ninety-Nine) Equity Shares of face value Rs.10/- each. For details of the Capital Structure, see **"Capital Structure"** on the page 73 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company, Saurabh Garg – 37,500 equity shares, Amita Garg – 10,000 equity shares and Pushplata Garg– 2,500 equity shares, aggregating to 50,000 Equity Shares of face value of Rs.10/- each. Details of the main objects of the Company as contained in the Memorandum of Association, see "History and Corporate Structure" on page 154 of the Red Herring Prospectus. For details of the share capital and capital structure of the Company see **"Capital Structure"** on page 73 of the Red Herring Prospectus.

LISTING: The Equity Shares Issued through the Red Herring Prospectus are proposed to be listed on the SME Platform of National Stock Exchange Of India Limited (**"NSE EMERGE"**). Our Company has received an "In-principle" approval from the National Stock Exchange Of India Limited for the listing of the Equity Shares pursuant to letter dated January 22, 2026. For the purposes of the Issue, the Designated Stock Exchange shall be National Stock Exchange Of India Limited (**"NSE EMERGE"**). A signed copy of the Red Herring Prospectus has been filed and the Prospectus shall be filed with the RoC in accordance with Section 26 and Section 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus until the Bid/ Issue Closing Date, see **"Material Contracts and Documents for Inspection"** beginning on page 383 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018. The Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Issue Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 322 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE):

"It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the "Disclaimer Clause of NSE."

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to **"Risk Factors"** on page 20 of the Red Herring Prospectus.

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issue was closed below the Issue/ Issue Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	62	4 (SME)
Share India Capital Services Private Limited	-	14	4
Common*	-	1	-
Total	2	77	8

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

Our Company was originally incorporated as “POCT Services Private Limited” on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to “Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to “Q-Line Biotech Limited”, and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **“History and Corporate Structure”** beginning on page 154 of the Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com
CIN: U74120UP2010PLC042528

Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF Q-LINE BIOTECH LIMITED (“OUR COMPANY” OR “QLBL” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹[●] LAKHS (“PUBLIC ISSUE”) OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Our Company has undertaken a Pre-IPO Placement by way of private placement of 8,00,000 Equity Shares for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.

**Subject to finalization of Basis of Allotment.*

PRICE BAND: ₹ 326 TO ₹ 343 PER EQUITY SHARE OF FACE VALUE ₹10/- EACH

THE FLOOR PRICE (₹326) IS 32.6 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE (₹343) IS 34.3 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.
THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE (₹326) IS 11.39 TIMES AND AT THE CAP PRICE (₹343) IS 11.98 TIMES.
BIDS CAN BE MADE FOR A MINIMUM OF 800 EQUITY SHARES AND IN MULTIPLES OF 400 EQUITY SHARES THEREAFTER

Weighted average return on net worth for the last three fiscal years should be read as 23.17%

The details of the Fresh Issue and the post-Issue market Capitalisation of the Company, each at the Floor Price (₹326) and the Cap Price (₹343), are given below:

Particular	At Floor price of ₹326 per equity share		At Cap price of ₹343 per equity share	
	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)
Fresh Issue	62,53,200	20,385.43	62,53,200	21,448.48
Offer for Sale	-	-	-	-
Total Issue Size	62,53,200	20,385.43	62,53,200	21,448.48
Post-Issue Market Capitalization of the Company	2,33,28,199	76,049.93	2,33,28,199	80,015.72

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENS ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSES ON: MONDAY, MAY 25, 2026 ^

^UPI mandate end time shall be at 05:00 p.m. on the Bid/Issue closing date.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

THIS ISSUE IS BEING MADE THROUGH BOOK BUILDING PROCESS, IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE “SEBI (ICDR) REGULATIONS”), AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACT (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”). FOR THE PURPOSE OF THE ISSUE, THE DESIGNATED STOCK EXCHANGE WILL BE NATIONAL STOCK EXCHANGE OF INDIA LIMITED.

ALLOCATION OF THE ISSUE

- **QIB PORTION** : NOT MORE THAN 50.00% OF THE NET ISSUE
- **NON-INSTITUTIONAL PORTION** : NOT LESS THAN 15.00% OF THE NET ISSUE
- **INDIVIDUAL PORTION** : NOT LESS THAN 35.00% OF THE NET ISSUE
- **MARKET MAKER PORTION** : UPTO 3,13,200 EQUITY SHARES OR 5.01% OF THE ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER, potential investors should only refer to this pre-issue and price band advertisement for the issue and should not rely on any media articles/ reports in relation to the valuation of the company as these are not endorsed, published or confirmed either by the company or the Book Running Read Manager to the issue (“BRLM”).

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated May 16, 2026 the above provided price band is justified based on quantitative factors/ KPIs disclosed in the **‘Basis for Issue Price’** section beginning on page 95 of the Red Herring Prospectus (“RHP”) vis-a-vis the weighted average cost of acquisition (“WACA”) of primary and secondary transaction(s), as applicable, disclosed in **‘Basis for Issue Price’** section beginning on page 95 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS

For details refer to section titled “Risk Factors” on page 20 of the Red Herring Prospectus.

1. Risk to investors summary description of key risk factors based on materiality

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
 - Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
 - Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
 - We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
 - We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
 - For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
 - Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
 - Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
 - Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
 - We are subject to risks arising from exchange rate fluctuations.
- Average cost of acquisition of Equity Shares held by the Individual Promoters are:

Sr. No.	Name of Promoter	No. of Shares held	Average Cost of Acquisition (in ₹)
1.	Saurabh Garg	1,01,91,000	0.04
2.	Amita Garg	39,37,480	0.00
3.	Ayush Garg	31,500	0.00
4.	Ajay Kumar Mahanty	7,50,000	18.34
5.	Abhay Agrawal	7,56,010	0.00

And the Issue Price at the upper end of the Price Band is Rs. 343 per Equity Share.

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.

2. Details of suitable ratios of the company and its peer group for the latest full financial year:

Name of Company	Current Market Price (₹)	Face Value	EPS	PE	RoNW (%)	Book Value (₹)	Total Income (₹ In lakhs)
			Basic/Diluted				
Q-line Biotech Limited	[●]*	10	28.63	[●]^	23.74%	120.60	31,378.04

**CMP of our Company is considered as Issue Price. ^to be included post Finalization of the Issue Price.*

Notes:

- The P/E ratio has been computed by dividing Market Price with EPS.
 - The EPS, NAV, RoNW and total Income of our Company are taken as per Consolidated Restated Financial Statement for the Year March 31, 2025.
 - NAV per share is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2025.
 - RoNW has been computed as net profit after tax divided by closing net worth.
 - Net worth has been computed in the manner as specifies in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.
 - The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [●] times the face value of equity share.
- 3. Weighted average return on net worth for the last 3 FYs:**
As per restated financial statements:

Sr. No.	Period	RONW (%)	Weights
1.	Period ending March 31, 2025	23.74	3
2.	Period ending March 31, 2024	21.29	2
3.	Period ending March 31, 2023	25.20	1
	Weighted Average	23.17	6
4.	For the period ended December 31, 2025	16.88	

Note:

- The figures disclosed above are based on the Restated Consolidated Financial Statements of the Company.
- The RoNW has been computed by dividing restated net profit after tax (excluding exceptional items) attributable to owners of parent company with restated Net worth as at the end of the year/period.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.
- Weighted average cost of acquisition of all the shares transacted in the three years, 18 months and one year preceding the date of the Red Herring Prospectus-**

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price(in Rs.)
Last one year, Last 18 months & Last 3 years	17.88	19.18	0-343

5. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI:

a) The price per share of our Company based on the primary/ new issue of shares (equity/ convertible securities)

There has been no issuance of Equity Shares other than Equity Shares issued pursuant to a private placement on May 13, 2026, bonus issue on August 28, 2025 and right issue on September 27, 2025 during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale/ acquisition of shares (equity shares)

There have been no secondary sale/ acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days

c) Price per share based on the last five Primary Issuances or Secondary Transactions

Since there are no such transactions to report to under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter/ Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of the Red Herring Prospectus irrespective of the size of transactions, is as below:

Primary Transaction:

Date of Allotment	No. of equity shares allotted	Issue price per equity share (₹)	Nature of Allotment	Nature of consideration	Total Consideration
August 28, 2025	1,41,75,000	Nil	Bonus Issue	-	Nil
September 27, 2025	5,24,999	10/-	Right Issue	Cash	52,49,990
May 13, 2026	8,00,000	343/-	Private Placement	Cash	27,44,00,000

Secondary Transaction:

Date	Name of Transferor	Name of Transferee	No. of Shares	Price per share	Adjusted Price per share	Nature of transaction	Total Consideration
September 25, 2025	Pushplata Garg	Saurabh Garg	54,000	Nil	-	Gift	Nil
		Abhay Agrawal	75,600	Nil	-	Gift	Nil
June 06, 2025	Amita Garg	Amit Agarwal	3,150	Nil	-	Gift	Nil
		Ayush Garg	3,149	Nil	-	Gift	Nil
	Saurabh Garg	Shubham Garg	3,150	Nil	-	Gift	Nil

Continued on next page

Continued from previous page

Weighted average cost of acquisition & Issue price			
Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs 10/-)	Floor price (i.e. ₹326)	Cap price (i.e. ₹343)
Weighted average cost of acquisition of primary / new issue	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale / acquisition.	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances/ secondary transactions	17.89	18.22	19.17

Note:
^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Red Herring Prospectus.
^^There were no secondary transactions in last 18 months from the date of the Red Herring Prospectus.
The Issue Price shall be determined by our Company in consultation with the BRLM, on the basis of the demand from investor for the Equity Shares through Book Building Process.

ADDITIONAL INFORMATION FOR INVESTORS:			
1. Details of proposed /undertaken pre-issue placements from the DRHP filing date - Our Company has undertaken a Pre-IPO Placement by way of private placement of 8,00,000 Equity Shares (4.92% of Pre Issue Capital) for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.			
Date of Allotment	Number of Equity Shares Allotted @ 343/-	Total Consideration	Name of Allottees
13.05.2026	4,35,502	14,93,77,186	Vikas Vijaykumar Khemani
	2,33,300	8,00,21,900	Calliope Capital Advisors LLP
	29,155	1,00,00,165	Sahastraa Advisors Private Limited
	29,155	1,00,00,165	SB Opportunities Fund II
	29,155	1,00,00,165	Deepak Malik
	29,155	1,00,00,165	Nisha Jain and Priyanka Havelia
	7,289	25,00,127	Kunal Niranjan Shah
	7,289	25,00,127	Rajkumar Mangilal Borana

- 2 Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date:** Not Applicable
- 3. Pre Issue Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company:**

S. No.	Pre-issue shareholding as at the date of Advertisement ⁽²⁾			Post-issue shareholding as at Allotment ⁽³⁾			
	Shareholders	Number of Equity Shares (2)	Share holding (in%) (2)	At the lower end of the price band (₹326) Number of Equity Shares (2)	Share holding (in %) (2)	At the upper end of the price band (₹343) Number of Equity Shares (2)	Share holding (in %) (2)
PROMOTER							
1.	Saurabh Garg	1,01,91,000	59.68	1,01,91,000	43.69%	1,01,91,000	43.69%
	Amita Garg	39,37,480	23.06	39,37,480	16.88%	39,37,480	16.88%
	Abhay Agrawal	7,56,010	4.43	7,56,010	3.24%	7,56,010	3.24%
	Ajay Kumar Mahanty	7,50,000	4.39	7,50,000	3.21%	7,50,000	3.21%
	Ayush Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
PROMOTER GROUP⁽²⁾							
2.	Amit Agarwal	31,510	0.18	31,510	0.14%	31,510	0.14%
	Shubham Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
	Pushplata Garg	21,000	0.12	21,000	0.09%	21,000	0.09%
ADDITIONAL TOP 10 SHAREHOLDERS							
3.	Vikas Vijaykumar Khemani	4,35,502	2.55	4,35,502	1.87%	4,35,502	1.87%
4.	Calliope Capital Advisors LLP	2,33,300	1.37	2,33,300	1.00%	2,33,300	1.00%
5.	Alok Kumar Agarwal	2,09,400	1.23	2,09,400	0.90%	2,09,400	0.90%
6.	Bishal Kumar	50,000	0.29	50,000	0.21%	50,000	0.21%
7.	Rajesh Kumar Upadhyay	40,000	0.23	40,000	0.17%	40,000	0.17%
8.	Dinesh Kantilal Doshi	32,000	0.19	32,000	0.14%	32,000	0.14%
9.	Bhupendra Singh Chuphal	32,000	0.19	32,000	0.14%	32,000	0.14%
10.	Amit Saraswat	32,000	0.19	32,000	0.14%	32,000	0.14%
11.	Anita Singhal	30,000	0.18	30,000	0.13%	30,000	0.13%
12.	Monika Raj	30,000	0.18	30,000	0.13%	30,000	0.13%
Total		1,68,74,202	98.82	1,68,74,202	72.33	1,68,74,202	72.33

- Notes:**
- 1) The Promoter Group shareholder is Pushplata Garg, Amit Agarwal and Shubham Garg.
- 2) Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.
- 3) Based on the Issue price of ₹(●) and subject to finalization of the basis of allotment.



BASIS FOR ISSUE PRICE

The ***"Basis of the Issue Price"*** on page 95 of the Offer document has been updated with the above price band. Please refer to the website of the BRLMs i.e. www.hemsecurities.com and www.shareindia.com for the ***"Basis of the Issue Price"*** updated with the above price band.
(You may scan the QR code for accessing the website of Hem Securities Limited and Share India Capital Services Private Limited)

INDICATIVE TIMELINE FOR THE ISSUE	
Our Company may in consultation with the BRLM, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations.	
Sequence of Activities	Listing within T+3 days (T is Issue Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Upto 4 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc.) – Upto 4 pm on T Day. Electronic Applications (Syndicate Individual Bidders, Non-Institutional Applications) – Upto 3 pm on T Day. Physical Applications (Bank ASBA) – Upto 1 pm on T Day. Physical Applications (Syndicate Individual Bidders, Non-Institutional Applications of QIBs and NIIs) – Upto 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day.
Bid Modification	From Issue opening date up to 4 pm on T Day.
Validation of bid details with depositories	From Issue opening date up to 5 pm on T Day.
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges –Sponsor Banks – NPCI and NPCI – PSPs/TPAPs* – Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timelines.	On daily basis
UPI Mandate acceptance time	T Day– 5 pm
Issue Closure T day	T Day – 4 pm for Individual Investor, QIB, NII and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day
Third party check on Non-UPI applications	On daily basis and to be completed before 1 pm on T+1 day
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA UPI ASBA	Before 09:30 pm on T+1 day All SCSBs for Direct ASBA – Before 07:30 pm on T Day Syndicate ASBA - Before 07:30 pm on T Day
Finalization of rejections and completion of basis	Before 6 pm on T+1 day.
Approval of basis by Stock Exchange	Before 9 pm on T+1 day
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer; Completion before 4 pm on T+2 day for unlocking
Corporate action execution for credit of shares	Initiation before 2 pm on T+2 day Completion before 6 pm on T+2 day
Filing of listing application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day. In newspapers - on T+3 day but not later than T+4 day
Trading starts T+3 day	T+3 day

BOOK RUNNING LEAD MANAGERS TO THE ISSUE		REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 Hem Securities	 Share India <i>You generate, we multiply</i>	 Purva Sharegistry	 Q-line Biotech <i>Spreading Healthiness!</i>
HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91-22-4906 0000 Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Sourabh Garg SEBI Registration Number: INM000010981 CIN: U67120RJ1995PLC010390	SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED Address: A 25, Basement, Sector 64, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301 Tel No.: +91 0120-6483000 Email: mb@shareindia.com Website: www.shareindia.com Contact Person: Kunal Bansal SEBI Reg. No.: INM000012537	PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22-2301-2517 / 8261 Fax No.: +91-022-23012517 Email: newissue@shareindia.com Website: www.purvashare.com Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112	Akhand Pratap Singh Q-LINE BIOTECH LIMITED Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012 Telephone: +91 522-2435570 Email: akhand.singh@qlinebiotech.com Website: www.qlinebiotech.com ; CIN: U74120UP2010PLC042528 Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post-Issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non- receipt of funds by electronic mode, etc. For all Issue related queries and for redressal of complaints investors may also write to the BRLMS.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of SEBI at <https://www.sebi.gov.in/>, website of the Company at www.qlinebiotech.com, the website of the BRLM to the Issue at <https://www.hemsecurities.com/>, the website of NSE at www.nseindia.com respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, BRLMs and NSE at www.qlinebiotech.com, <https://www.hemsecurities.com>, www.shareindia.com and www.nseindia.com, respectively.

SYNDICATE MEMBER: Hem Finlease Private Limited

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Q-Line Biotech Limited, Telephone: +91 522-2435570; BRLM: Hem Securities Limited, Telephone: +91-22-4906 0000 and the Syndicate Members: Hem Finlease Private Limited, Telephone: +91-141-4051000 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

BANKER TO THE ISSUE ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: HDFC Bank Limited.

UPI: UPI Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

Place: Lucknow, Uttar Pradesh
Date: May 16, 2026.

Disclaimer- Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares the Red Herring Prospectus dated May 16, 2026 has been filed with the Registrar of Companies, Uttar Pradesh-I and thereafter with SEBI and the Stock Exchanges. The Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE at www.nseindia.com and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled ***"Risk Factors"*** beginning on page 20 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the ***"Securities Act"***) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public Issuing in the United States.

On behalf of Board of Directors
Q-Line Biotech Limited
Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

Our Company was originally incorporated as “POCT Services Private Limited” on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to “Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to “Q-Line Biotech Limited”, and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **“History and Corporate Structure”**beginning on page 154 of the Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com
CIN: U74120UP2010PLC042528

Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF Q-LINE BIOTECH LIMITED (“OUR COMPANY” OR “QLBL” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹[●] LAKHS (“PUBLIC ISSUE”) OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Our Company has undertaken a Pre-IPO Placement by way of private placement of 8,00,000 Equity Shares for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.

**Subject to finalization of Basis of Allotment.*

PRICE BAND: ₹ 326 TO ₹ 343 PER EQUITY SHARE OF FACE VALUE ₹10/- EACH

**THE FLOOR PRICE (₹326) IS 32.6 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE (₹343) IS 34.3 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.
THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE (₹326) IS 11.39 TIMES AND AT THE CAP PRICE (₹343) IS 11.98 TIMES.
BIDS CAN BE MADE FOR A MINIMUM OF 800 EQUITY SHARES AND IN MULTIPLES OF 400 EQUITY SHARES THEREAFTER**

Weighted average return on net worth for the last three fiscal years should be read as 23.17%

The details of the Fresh Issue and the post-Issue market Capitalisation of the Company, each at the Floor Price (₹326) and the Cap Price (₹343), are given below:

Particular	At Floor price of ₹326 per equity share		At Cap price of ₹343 per equity share	
	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)	Up to No of equity Shares of face value of Rs. 10/- each	Up to amount (Rs in Lakhs)
Fresh Issue	62,53,200	20,385.43	62,53,200	21,448.48
Offer for Sale	-	-	-	-
Total Issue Size	62,53,200	20,385.43	62,53,200	21,448.48
Post-Issue Market Capitalization of the Company	2,33,28,199	76,049.93	2,33,28,199	80,015.72

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENS ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSES ON: MONDAY, MAY 25, 2026 ^

^UPI mandate end time shall be at 05:00 p.m. on the Bid/Issue closing date.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

THIS ISSUE IS BEING MADE THROUGH BOOK BUILDING PROCESS, IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE “SEBI (ICDR) REGULATIONS”), AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACT (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”)

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE EMERGE”). FOR THE PURPOSE OF THE ISSUE, THE DESIGNATED STOCK EXCHANGE WILL BE NATIONAL STOCK EXCHANGE OF INDIA LIMITED.

ALLOCATION OF THE ISSUE

- **QIB PORTION** : NOT MORE THAN 50.00% OF THE NET ISSUE
 - **INDIVIDUAL PORTION** : NOT LESS THAN 35.00% OF THE NET ISSUE
- **NON-INSTITUTIONAL PORTION** : NOT LESS THAN 15.00% OF THE NET ISSUE
 - **MARKET MAKER PORTION** : UPTO 3,13,200 EQUITY SHARES OR 5.01% OF THE ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER, potential investors should only refer to this pre-issue and price band advertisement for the issue and should not rely on any media articles/ reports in relation to the valuation of the company as these are not endorsed, published or confirmed either by the company or the Book Running Read Manager to the issue (“BRLM”).

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated May 16, 2026 the above provided price band is justified based on quantitative factors/ KPIs disclosed in the ‘**Basis for Issue Price**’ section beginning on page 95 of the Red Herring Prospectus (‘RHP’) vis-a-vis the weighted average cost of acquisition (‘WACA’) of primary and secondary transaction(s), as applicable, disclosed in ‘**Basis for Issue Price**’ section beginning on page 95 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS

For details refer to section titled “Risk Factors” on page 20 of the Red Herring Prospectus.

1. Risk to investors summary description of key risk factors based on materiality

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
 - Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
 - Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
 - We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
 - We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
 - For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
 - Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
 - Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
 - Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
 - We are subject to risks arising from exchange rate fluctuations.
- Average cost of acquisition of Equity Shares held by the Individual Promoters are:

Sr. No.	Name of Promoter	No. of Shares held	Average Cost of Acquisition (in ₹)
1.	Saurabh Garg	1,01,91,000	0.04
2.	Amita Garg	39,37,480	0.00
3.	Ayush Garg	31,500	0.00
4.	Ajay Kumar Mahanty	7,50,000	18.34
5.	Abhay Agrawal	7,56,010	0.00

And the Issue Price at the upper end of the Price Band is Rs. 343 per Equity Share.

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.

2. Details of suitable ratios of the company and its peer group for the latest full financial year:

Name of Company	Current Market Price (₹)	Face Value	EPS	PE	RoNW (%)	Book Value (₹)	Total Income (₹ In lakhs)
			Basic/Diluted				
Q-line Biotech Limited	[●]*	10	28.63	[●]^	23.74%	120.60	31,378.04

**CMP of our Company is considered as Issue Price. ^to be included post finalization of the Issue Price.*

Notes:

- The P/E ratio has been computed by dividing Market Price with EPS.
 - The EPS, NAV, RoNW and total Income of our Company are taken as per Consolidated Restated Financial Statement for the Year March 31, 2025.
 - NAV per share is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2025.
 - RoNW has been computed as net profit after tax divided by closing net worth.
 - Net worth has been computed in the manner as specifies in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.
 - The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [●] times the face value of equity share.
- 3. Weighted average return on net worth for the last 3 FYs:**
As per restated financial statements:

Sr. No.	Period	RoNW (%)	Weights
1.	Period ending March 31, 2025	23.74	3
2.	Period ending March 31, 2024	21.29	2
3.	Period ending March 31, 2023	25.20	1
	Weighted Average	23.17	6
4.	For the period ended December 31, 2025	16.88	

Note:

- The figures disclosed above are based on the Restated Consolidated Financial Statements of the Company.
- The RoNW has been computed by dividing restated net profit after tax (excluding exceptional items) attributable to owners of parent company with restated Net worth as at the end of the year/period.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.

4. Weighted average cost of acquisition of all the shares transacted in the three years, 18 months and one year preceding the date of the Red Herring Prospectus-

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price(in Rs.)
Last one year, Last 18 months & Last 3 years	17.88	19.18	0-343

5. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI:

a) The price per share of our Company based on the primary/ new issue of shares (equity/ convertible securities)

There has been no issuance of Equity Shares other than Equity Shares issued pursuant to a private placement on May 13, 2026, bonus issue on August 28, 2025 and right issue on September 27, 2025 during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale/ acquisition of shares (equity shares)

There have been no secondary sale/ acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days

c) Price per share based on the last five Primary Issuances or Secondary Transactions

Since there are no such transactions to report to under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter/ Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of the Red Herring Prospectus irrespective of the size of transactions, is as below:

Primary Transaction:

Date of Allotment	No. of equity shares allotted	Issue price per equity share (₹)	Nature of Allotment	Nature of consideration	Total Consideration
August 28, 2025	1,41,75,000	Nil	Bonus Issue	-	Nil
September 27, 2025	5,24,999	10/-	Right Issue	Cash	52,49,990
May 13, 2026	8,00,000	343/-	Private Placement	Cash	27,44,00,000

Secondary Transaction:

Date	Name of Transferor	Name of Transferee	No. of Shares	Price per share	Adjusted Price per share	Nature of transaction	Total Consideration
September 25, 2025	Pushplata Garg	Saurabh Garg	54,000	Nil	-	Gift	Nil
June 06, 2025	Amita Garg	Abhay Agrawal	75,600	Nil	-	Gift	Nil
		Amit Agarwal	3,150	Nil	-	Gift	Nil
	Saurabh Garg	Ayush Garg	3,149	Nil	-	Gift	Nil
		Shubham Garg	3,150	Nil	-	Gift	Nil

Continued on next page

Continued from previous page

Weighted average cost of acquisition & Issue price			
Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs 10/-)	Floor price (i.e. ₹326)	Cap price (i.e. ₹343)
Weighted average cost of acquisition of primary / new issue	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale / acquisition.	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances/ secondary transactions	17.89	18.22	19.17

Note:
^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Red Herring Prospectus.
^^There were no secondary transactions in last 18 months from the date of the Red Herring Prospectus.
The Issue Price shall be determined by our Company in consultation with the BRLM, on the basis of the demand from investor for the Equity Shares through Book Building Process.

ADDITIONAL INFORMATION FOR INVESTORS:			
1. Details of proposed /undertaken pre-Issue placements from the DRHP filing date - Our Company has undertaken a Pre-IPO Placement by way of private placement of 8,00,000 Equity Shares (4.92% of Pre Issue Capital) for cash at a price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 Lakhs, in consultation with the BRLMs, pursuant to the Board meeting dated May 13, 2026 from the DRHP filing date.			
Date of Allotment	Number of Equity Shares Allotted @ 343/-	Total Consideration	Name of Allottees
13.05.2026	4,35,502	14,93,77,186	Vikas Vijaykumar Khemani
	2,33,300	8,00,21,900	Calliope Capital Advisors LLP
	29,155	1,00,00,165	Sahastraa Advisors Private Limited
	29,155	1,00,00,165	SB Opportunities Fund II
	29,155	1,00,00,165	Deepak Malik
	29,155	1,00,00,165	Nisha Jain and Priyanka Havelia
	7,289	25,00,127	Kunal Niranjan Shah
	7,289	25,00,127	Rajkumar Mangilal Borana

- 2 Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date:** Not Applicable
- 3. Pre Issue Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company:**

S. No.	Pre-Issue shareholding as at the date of Advertisement ⁽²⁾			Post-Issue shareholding as at Allotment ⁽³⁾			
	Shareholders	Number of Equity Shares (2)	Share holding (in%) (2)	At the lower end of the price band (₹326)		At the upper end of the price band (₹343)	
				Number of Equity Shares (2)	Share holding (in %) (2)	Number of Equity Shares (2)	Share holding (in %) (2)
PROMOTER							
1.	Saurabh Garg	1,01,91,000	59.68	1,01,91,000	43.69%	1,01,91,000	43.69%
	Amita Garg	39,37,480	23.06	39,37,480	16.88%	39,37,480	16.88%
	Abhay Agrawal	7,56,010	4.43	7,56,010	3.24%	7,56,010	3.24%
	Ajay Kumar Mahanty	7,50,000	4.39	7,50,000	3.21%	7,50,000	3.21%
	Ayush Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
PROMOTER GROUP⁽¹⁾							
2.	Amit Agarwal	31,510	0.18	31,510	0.14%	31,510	0.14%
	Shubham Garg	31,500	0.18	31,500	0.14%	31,500	0.14%
	Pushplata Garg	21,000	0.12	21,000	0.09%	21,000	0.09%
ADDITIONAL TOP 10 SHAREHOLDERS							
3.	Vikas Vijaykumar Khemani	4,35,502	2.55	4,35,502	1.87%	4,35,502	1.87%
4.	Calliope Capital Advisors LLP	2,33,300	1.37	2,33,300	1.00%	2,33,300	1.00%
5.	Alok Kumar Agarwal	2,09,400	1.23	2,09,400	0.90%	2,09,400	0.90%
6.	Bishal Kumar	50,000	0.29	50,000	0.21%	50,000	0.21%
7.	Rajesh Kumar Upadhyay	40,000	0.23	40,000	0.17%	40,000	0.17%
8.	Dinesh Kantilal Doshi	32,000	0.19	32,000	0.14%	32,000	0.14%
9.	Bhupendra Singh Chuphal	32,000	0.19	32,000	0.14%	32,000	0.14%
10.	Amit Saraswat	32,000	0.19	32,000	0.14%	32,000	0.14%
11.	Anita Singhal	30,000	0.18	30,000	0.13%	30,000	0.13%
12.	Monika Raj	30,000	0.18	30,000	0.13%	30,000	0.13%
	Total	1,68,74,202	98.82	1,68,74,202	72.33	1,68,74,202	72.33





- Notes:**
- The Promoter Group shareholder is Pushplata Garg, Amit Agarwal and Shubham Garg.
 - Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.
 - Based on the Issue price of ₹(●) and subject to finalization of the basis of allotment.



BASIS FOR ISSUE PRICE

The **"Basis of the Issue Price"** on page 95 of the Offer document has been updated with the above price band. Please refer to the website of the BRLMs i.e. www.hemsecurities.com and www.shareindia.com for the **"Basis of the Issue Price"** updated with the above price band.
(You may scan the QR code for accessing the website of Hem Securities Limited and Share India Capital Services Private Limited)

INDICATIVE TIMELINE FOR THE ISSUE	
Our Company may in consultation with the BRLM, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations.	
Sequence of Activities	Listing within T+3 days (T is Issue Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Upto 4 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc.) – Upto 4 pm on T Day. Electronic Applications (Syndicate Individual Bidders, Non-Institutional Applications) – Upto 3 pm on T Day. Physical Applications (Bank ASBA) – Upto 1 pm on T Day. Physical Applications (Syndicate Individual Bidders, Non-Institutional Applications of QIBs and NIIs) – Upto 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day.
Bid Modification	From Issue opening date up to 4 pm on T Day.
Validation of bid details with depositories	From Issue opening date up to 5 pm on T Day.
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges –Sponsor Banks – NPCI and NPCI – PSPs/TPAPs* – Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timelines.	On daily basis
UPI Mandate acceptance time	T Day– 5 pm
Issue Closure T day	T Day – 4 pm for Individual Investor, QIB, NII and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day
Third party check on Non-UPI applications	On daily basis and to be completed before 1 pm on T+1 day
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA UPI ASBA	Before 09:30 pm on T+1 day All SCSBs for Direct ASBA – Before 07:30 pm on T Day Syndicate ASBA - Before 07:30 pm on T Day
Finalization of rejections and completion of basis	Before 6 pm on T+1 day.
Approval of basis by Stock Exchange	Before 9 pm on T+1 day
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer; Completion before 4 pm on T+2 day for unlocking
Corporate action execution for credit of shares	Initiation before 2 pm on T+2 day Completion before 6 pm on T+2 day
Filing of listing application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day. In newspapers - on T+3 day but not later than T+4 day
Trading starts T+3 day	T+3 day

BOOK RUNNING LEAD MANAGERS TO THE ISSUE		REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 Hem Securities	 Share India <i>You generate, we multiply</i>	 Purva Sharegistry	 Q-line Biotech <i>Spreading Healthiness!</i>
HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91-22-4906 0000 ; Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Sourabh Garg SEBI Registration Number: INM000010981 CIN: U67120RJ1995PLC010390	SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED Address: A 25, Basement, Sector 64, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301 Tel No.: +91 0120-6483000 Email: mb@shareindia.com Website: www.shareindia.com Contact Person: Kunal Bansal SEBI Reg. No.: INM000012537	PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22-2301-2517 / 8261 Fax No.: +91-022-23012517 Email: newissue@shareindia.com Website: www.purvashare.com Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112	Akhand Pratap Singh Q-LINE BIOTECH LIMITED Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012 ; Telephone: +91 522-2435570 ; Email: akhand.singh@qlinebiotech.com Website: www qlinebiotech.com ; CIN: U74120UP2010PLC042528 Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post-Issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non- receipt of funds by electronic mode, etc. For all Issue related queries and for redressal of complaints investors may also write to the BRLMs.
<p>AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of SEBI at https://www.sebi.gov.in/, website of the Company at www qlinebiotech.com, the website of the BRLM to the Issue at https://www.hemsecurities.com/, the website of NSE at www.nseindia.com respectively.</p> <p>AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, BRLMs and NSE at www qlinebiotech.com, https://www.hemsecurities.com, www.shareindia.com and www.nseindia.com, respectively.</p> <p>SYNDICATE MEMBER: Hem Finlease Private Limited</p> <p>AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Q-Line Biotech Limited, Telephone: +91 522-2435570; BRLM: Hem Securities Limited, Telephone: +91-22-4906 0000 and the Syndicate Members: Hem Finlease Private Limited, Telephone: +91-141-4051000 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.</p> <p>BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: HDFC Bank Limited.</p> <p>UPI: UPI Bidders can also Bid through UPI Mechanism.</p> <p>All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.</p>			
<p>Place: Lucknow, Uttar Pradesh Date: May 16, 2026.</p> <p>Disclaimer- Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares the Red Herring Prospectus dated May 16, 2026 has been filed with the Registrar of Companies, Uttar Pradesh-I and thereafter with SEBI and the Stock Exchanges. The Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE at www.nseindia.com/companies-listing/corporate-filings-offer-documents and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled "Risk Factors" beginning on page 20 of the Red Herring Prospectus.</p> <p>The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public listing in the United States.</p>			
<p style="text-align: right;">On behalf of Board of Directors Q-Line Biotech Limited Sd/- Akhand Pratap Singh Company Secretary and Compliance Officer</p>			